Competing interests
MAB is an employee of and stockholder in Eli Lilly & Co. HS has received grant support from Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi as well as personal fees from AstraZeneca, Amgen, Boehringer Ingelheim, Bayer, Eli Lilly, MSD, Novartis, NovoNordisk, Sanofi Aventis. YL has received grants from Merck, Janssen Research & Development, AstraZeneca, GlaxoSmithKline, and Bayer HealthCare AG. EDP has received research support from Janssen, Merck, Bristol Myers Squibb, Amgen, and Esperion, and has had consulting associations with Bristol Myers Squibb, Pfizer, Amgen, Janssen, Boehringer-Ingelheim, and Livongo. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmacueticals, Bayer, Novartis and Novo Nordisk. RDL has received research grants from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, and Pfizer; consulting fees from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, and Portola Pharmaceutical. The other authors have no disclosures.